About GPS Cancer®
GPS Cancer is a unique, comprehensive molecular test available through NantHealth. GPS Cancer integrates tumor-normal sequencing of DNA (whole genome/exome) with transcriptome (RNA) sequencing, providing oncologists with a comprehensive molecular profile of a patient’s cancer to inform personalized treatment strategies.
Why whole genome/exome sequencing?
Genomics is the study of the structure and function of the genome—that is, the full set of DNA in a cell—and is at the core of precision cancer care. Through DNA sequencing, it is possible to better understand what alterations (e.g., base pair changes, deletions, duplications, insertions, etc.) cause a cell to become cancerous, and ultimately, help identify targeted treatments.
Today, many available tests employ limited gene panels of 10-400 genes. With limited information from these smaller panels, oncologists may not have a comprehensive profile of the patient's cancer. On the other hand, GPS Cancer sequences the whole genome or exome of 20,000 genes and 3 billion base pairs, providing oncologists with an expansive view of alterations to inform personalized treatment strategies for patients.
Why tumor-normal matching?
Most genomic analysis tests employ a reference genome against which a patient’s tumor DNA is compared to identify alterations. However, this reference genome is typically derived from a group of patient samples, which may not be representative of the diversity of the population. GPS Cancer offers “tumor-normal” whole genome sequencing, allowing comparison of tumor mutations to the patient's own normal blood sample to identify the genetic variants that drive cancer progression in that individual.
Why RNA sequencing?
DNA is the blueprint for RNA, and RNA is the blueprint for proteins. Sequencing RNA provides oncologists with insight into inferred protein expression. If the alterations identified in the patient’s tumor DNA are not identified in the tumor RNA, they will have no biological impact. Alterations in RNA may result in changes in protein expression, which will impact the treatment options for patients. GPS Cancer combines the power of both whole genome (DNA) and whole transcriptome (RNA) sequencing of more than 200,000 RNA transcripts.